TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

DEY

OphthalmologyInfectious DiseaseOncology
Generics

DEY is a generic drug manufacturer focused on Ophthalmology, Infectious Disease, Oncology.

1986
Since
6
Drugs
-
Trials
4
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

ISOPROTERENOL HYDROCHLORIDE 2025-12-10
ISOPROTERENOL HYDROCHLORIDE 2024-10-03
ISOPROTERENOL HYDROCHLORIDE 2024-08-22
Labeling
ISOPROTERENOL HYDROCHLORIDE 2024-08-06
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Ophthalmology 75%
0 drugs Phase 3: 7 Phase 2: 7
Infectious Disease 11%
0 drugs Phase 3: 1 Phase 2: 1
Oncology 7%
0 drugs Phase 3: 1
Immunology 4%
0 drugs Phase 2: 1
Respiratory 4%
0 drugs Phase 2: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Novartis big-pharma
Oncology, Immunology, Ophthalmology, Respiratory
AbbVie big-pharma
Immunology, Oncology, Infectious Disease, Ophthalmology
GSK big-pharma
Infectious Disease, Respiratory, Oncology, Immunology
Sanofi big-pharma
Oncology, Infectious Disease, Immunology, Respiratory
Roche big-pharma
Oncology, Ophthalmology, Immunology, Respiratory